Chemotherapy With or Without IMD10 (Focused Ultrasound) in the Treatment of Borderline Resectable or Locally Advanced Pancreatic Cancer

The purpose of this Interventional clinical trial is to evaluate safety and efficacy of 'IMD10 (focused ultrasound)' in the treatment of borderline resectable pancreatic cancer or locally advanced pancreatic cancer.

Trial Details

NCT ID
NCT07325214
Phase
NA
Sponsor
IMGT Co., Ltd.
Status
RECRUITING
Cancer Type
Pancreatic Cancer
Interventions
  • IMD10
  • chemotherapy regimen [irinotecan hydrochloride, oxaliplatin, fluorouracil (5-FU) and leucovorin]
Locations (sample)
  • Boston, Massachusetts, United States|42.35843,-71.05977
  • San Antonio, Texas, United States|29.42412,-98.49363
  • Charlottesville, Virginia, United States|38.02931,-78.47668
  • Gyeonggi-do, South Korea|37.58944,126.76917
  • Seoul, South Korea|37.566,126.9784

Key Eligibility Criteria

  • An individual must meet all the following criteria:
  • Willing and able to understand and sign an ICF and to comply with all aspects of the protocol
  • 2\. Aged between 18 and 85 years, inclusive
  • 3\. Histologically or cytologically, pathologically confirmed diagnosis of PDAC.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →